X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2242) 2242
Publication (245) 245
Book / eBook (126) 126
Book Review (102) 102
Book Chapter (52) 52
Newsletter (26) 26
Patent (16) 16
Dissertation (5) 5
Magazine Article (5) 5
Newspaper Article (3) 3
Conference Proceeding (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1360) 1360
index medicus (1222) 1222
animals (875) 875
steroids (799) 799
male (701) 701
female (632) 632
research (350) 350
steroid hormones (320) 320
medicine (314) 314
pharmacology & pharmacy (303) 303
research article (288) 288
gene expression (275) 275
multidisciplinary sciences (265) 265
mice (260) 260
rats (260) 260
cancer (256) 256
endocrinology & metabolism (248) 248
health aspects (246) 246
proteins (240) 240
corticosteroids (235) 235
science (235) 235
care and treatment (221) 221
hormones (211) 211
physiological aspects (206) 206
oncology (200) 200
adult (197) 197
metabolism (195) 195
middle aged (194) 194
inflammation (189) 189
rodents (188) 188
physiology (184) 184
biology (183) 183
expression (182) 182
review (182) 182
biochemistry & molecular biology (176) 176
enzymes (176) 176
analysis (173) 173
article (159) 159
signal transduction (157) 157
apoptosis (156) 156
estrogen (156) 156
studies (156) 156
androgens (155) 155
testosterone (155) 155
biochemistry (151) 151
glucocorticoids (149) 149
prostate cancer (149) 149
neurosciences (148) 148
gene-expression (145) 145
drug therapy (139) 139
risk factors (135) 135
aged (132) 132
treatment outcome (130) 130
pharmacology (127) 127
receptors (125) 125
genetic aspects (124) 124
progesterone (124) 124
cell line, tumor (123) 123
breast cancer (118) 118
cell biology (118) 118
in-vitro (117) 117
kinases (117) 117
inhibition (104) 104
dexamethasone (102) 102
chemistry (101) 101
chemistry, medicinal (101) 101
immunology (101) 101
therapy (101) 101
prostatic neoplasms - drug therapy (99) 99
cytokines (98) 98
dose-response relationship, drug (98) 98
tumors (97) 97
cells (96) 96
endocrinology (96) 96
genes (96) 96
medical research (95) 95
brain (92) 92
development and progression (91) 91
metabolites (90) 90
androgen receptor (88) 88
activation (87) 87
dosage and administration (87) 87
estrogens (87) 87
ligands (86) 86
cholesterol (83) 83
pregnancy (83) 83
abridged index medicus (82) 82
cells, cultured (81) 81
postmenopausal women (81) 81
steroid 17-alpha-hydroxylase - antagonists & inhibitors (81) 81
disease models, animal (80) 80
estradiol (80) 80
oxidative stress (80) 80
disease (79) 79
organic chemistry (79) 79
chemotherapy (78) 78
toxicology (78) 78
chemistry, multidisciplinary (77) 77
genetics (77) 77
hypertension (77) 77
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (102) 102
UofT at Mississauga - Stacks (9) 9
UTL at Downsview - May be requested (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
UofT at Scarborough - Stacks (3) 3
Online Resources - Online (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
OISE - Stacks (1) 1
Robarts - Stacks (1) 1
Royal Ontario Museum - May be requested (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
UofT at Mississauga - Periodical Stacks (1) 1
UofT at Scarborough - Withdrawn (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2450) 2450
French (14) 14
German (9) 9
Chinese (4) 4
Japanese (3) 3
Russian (2) 2
Spanish (2) 2
Danish (1) 1
Hebrew (1) 1
Italian (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 441 - 447
Abstract Background Although abiraterone acetate (abiraterone) has proven efficacy in two randomised phase 3 trials in metastatic castration-resistant prostate... 
Urology | Castration-resistant prostate cancer | Prostate cancer | Abiraterone acetate | ECOG | Performance status | PREDNISONE | MITOXANTRONE | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | CHEMOTHERAPY | Multivariate Analysis | Cytochrome P-450 Enzyme Inhibitors - therapeutic use | Humans | Middle Aged | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Kallikreins - blood | Retrospective Studies | Prostatic Neoplasms, Castration-Resistant - blood | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Steroid Synthesis Inhibitors - therapeutic use | Logistic Models | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostate-Specific Antigen - blood | Canada | Neoplasms, Hormone-Dependent - blood | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasms, Hormone-Dependent - drug therapy | Health Status | Care and treatment | Cancer patients | Metastasis | Acetates
Journal Article
European Urology, ISSN 0302-2838, 2015, Volume 68, Issue 4, pp. 570 - 577
Abstract Background Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall... 
Urology | Bone-targeted therapy | Metastatic castration-resistant prostate cancer | Chemotherapy-naïve | Abiraterone acetate | SURVIVAL | PLACEBO | Chemotherapy-naive | PHASE-3 | SKELETAL COMPLICATIONS | ANDROGEN-DEPRIVATION THERAPY | ZOLEDRONIC ACID | PREDNISONE | RECOMMENDATIONS | MEN | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | Bone Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Clinical Trials, Phase III as Topic | Multicenter Studies as Topic | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Retrospective Studies | Bone Neoplasms - drug therapy | Odds Ratio | Bone Density Conservation Agents - adverse effects | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Steroid Synthesis Inhibitors - therapeutic use | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Prednisone - therapeutic use | Cancer patients | Care and treatment | Chemotherapy | Oncology, Experimental | Analysis | Research | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article
European Urology, ISSN 0302-2838, 2017, Volume 72, Issue 1, pp. 10 - 13
Abstract In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic... 
Urology | Androgen signaling–directed therapy | Metastatic castration-resistant prostate cancer | Chemotherapy-naïve | Sequencing | Abiraterone acetate | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | Chemotherapy-naive | DOCETAXEL | CHEMOTHERAPY | prostate cancer | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Metastatic castration-resistant | Androgen signaling-directed therapy | ENZALUTAMIDE | Phenylthiohydantoin - adverse effects | Phenylthiohydantoin - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Clinical Trials, Phase III as Topic | Neoplasm Metastasis | Multicenter Studies as Topic | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Kallikreins - blood | Retrospective Studies | Prednisone - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Steroid Synthesis Inhibitors - therapeutic use | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Randomized Controlled Trials as Topic | Disease-Free Survival | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Prostatic Neoplasms, Castration-Resistant - mortality | Prednisone - therapeutic use | Medical research | Medical colleges | Care and treatment | Corticosteroids | Patient outcomes | Censorship | Prednisone | Metastasis | Acetates | Chemotherapy | Medicine, Experimental | Prostate cancer | Cancer | Steroids
Journal Article
Drugs, ISSN 0012-6667, 2001, Volume 61, Issue 4, pp. 499 - 514
Journal Article
Journal Article